文献类型：期刊文献

英文题名：Scoparone alleviates hepatic fibrosis by inhibiting the TLR-4/NF-kappa B pathway

作者：Gao, Ya[1];Xi, Boting[1];Li, Jiani[1];Li, Zimeng[1];Xu, Jie[1];Zhong, Mingli[1];Xu, Qiongmei[1];Lian, Yuanyu[1];Wei, Riming[1];Wang, Liping[1];Cao, Houkang[2];Jin, Ling[2];Zhang, Kefeng[1,2];Dong, Jianghui[1]

第一作者：Gao, Ya

通信作者：Zhang, KF[1];Dong, JH[1]

机构：[1]Guilin Med Univ, Coll Pharm, Guilin 541199, Guangxi, Peoples R China;[2]Gansu Univ Chinese Med, Coll Pharm, Lanzhou, Gansu, Peoples R China

第一机构：Guilin Med Univ, Coll Pharm, Guilin 541199, Guangxi, Peoples R China

通信机构：[1]corresponding author), Guilin Med Univ, Coll Pharm, Guilin 541199, Guangxi, Peoples R China.

年份：2021

卷号：236

期号：4

起止页码：3044

外文期刊名：JOURNAL OF CELLULAR PHYSIOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000577477400001)】；

基金：National Science Foundation of Guangxi Province of China, Grant/Award Numbers: 2017GXNSFAA198218, 2017GXNSFAA198326, 2018GXNSFAA281040; Special funding for 2017 Guangxi BaGui Scholars; National Natural Science Foundation of China, Grant/Award Numbers: 81660104, 81760114, 81860673, 81960779, 62061012

语种：英文

外文关键词：hepatic fibrosis; phosphorylation of nuclear factor-kappa B; scoparone; Toll-like receptor-4; nuclear factor kappa-B

摘要：The aim of this study was to investigate the role of scoparone (SCO) in hepatic fibrosis. For this, we conducted in vivo and in vitro experiments. In vivo rats that were divided into six groups, control, carbon tetrachloride, and colchicine, as well as SCO groups, SCO50, SCO100, and SCO200 treated with 50, 100, and 200 mg/kg SCO doses, respectively. Furthermore, SCO was shown to inhibit Toll-like receptor-4 (TLR-4)/nuclear factor kappa-B (NF-kappa B; TLR-4/NF-kappa B) signals by inhibiting TLR-4, which in turn downregulates the expression of MyD88, promotes NF-kappa B inhibitor-alpha, NF-kappa B inhibitor-beta, and NF-kappa B inhibitor-epsilon activation, while inhibiting NF-kappa B inhibitor-zeta. Subsequently, the decrease of phosphorylation of nuclear factor-kappa B levels leads to the downregulation of the downstream inflammatory factors' tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1 beta, thus weakening hepatic fibrosis. Notably, the SCO200 treated group presented the most significant improvement. Hence, we conclude that SCO alleviates hepatic fibrosis by inhibiting TLR-4/NF-kappa B signals.